AXOVANT GENE THERAPIES LTD's ticker is AXGT and the CUSIP is G0750W203. A total of 40 filers reported holding AXOVANT GENE THERAPIES LTD in Q2 2019. The put-call ratio across all filers is 0.99 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $544,000 | – | 409,738 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SPHERA FUNDS MANAGEMENT LTD. | 668,541 | $4,165,000 | 0.57% |
| Leap Investments LP | 18,400 | $115,000 | 0.16% |
| Hudson Bay Capital Management LP | 550,000 | $3,427,000 | 0.08% |
| BOOTHBAY FUND MANAGEMENT, LLC | 45,989 | $287,000 | 0.03% |
| GSA CAPITAL PARTNERS LLP | 25,561 | $159,000 | 0.02% |
| Spark Investment Management LLC | 37,000 | $230,000 | 0.02% |
| AMERICAN FINANCIAL GROUP INC | 10,774 | $67,000 | 0.01% |
| ExodusPoint Capital Management, LP | 13,700 | $85,000 | 0.00% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 125,000 | $779,000 | 0.00% |
| Renaissance Technologies | 329,823 | $2,055,000 | 0.00% |